Central Nervous System Neoplasms Clinical Trial
Official title:
A Multi-center, Prospective, Self-Controlled Diagnostic Accuracy Comparative Studies of Artificial Intelligence Diagnostic System for Surgical Neuropathology
This is a multi-center, prospective, self-controlled, diagnostic accuracy comparative study of Artificial Intelligence Diagnostic System for Surgical Neuropathology. The investigators will compare the diagnostic efficiency of Artificial Intelligence with that of practicing pathologists, and suppose that the diagnostic efficiency of artificial intelligence in prospective clinical data is no less than that of pathologists.
In this study, 141 patients will be recruited. After being enrolled, the patients will accept surgery and specimens for pathological analysis will be taken according to the routine treatment process. The histopathologic slides will then be digitized by a whole-slide scanner. The images will be reviewed by gold standard committee for evaluation of ground truth. And then be separately diagnosed by Artificial Intelligence Diagnostic System and practicing pathologists. So the investigators can compare the diagnostic efficiency of Artificial Intelligence with that of pathologists, thus understand the gap between artificial intelligence and actual clinical practice. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00329589 -
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients
|
Phase 1 | |
Completed |
NCT03257631 -
A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
|
Phase 2 | |
Terminated |
NCT02095353 -
Comparison of Contrast Agents for MRI Perfusion Analysis in Brain Tumor Patients
|
||
Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
Active, not recruiting |
NCT01180881 -
Neurobehavioral Functioning in Pediatric Brain Tumor Patients After Proton Beam Radiation Treatment
|
||
Completed |
NCT00822432 -
Coproporphyrine Isomers and Methotrexate Elimination
|
N/A | |
Completed |
NCT02291822 -
Retrospective Study of MRI in Pediatric Patients
|
N/A | |
Completed |
NCT03750188 -
Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs
|
||
Completed |
NCT03188354 -
Diagnostic Assessment of 18F-fluciclovine and 18F-FDG -PET/MRI of Primary Central Nervous System Lymphoma
|
N/A | |
Completed |
NCT03147989 -
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
|
||
Completed |
NCT03434262 -
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
|
Phase 1 | |
Not yet recruiting |
NCT05850377 -
5-Aminolevulinic Acid (5-ALA) Gliolan®: Usage Increase Proposal for Neurosurgical Procedures in High-Grade Gliomas
|
||
Terminated |
NCT01582152 -
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04525014 -
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
Phase 1 | |
Terminated |
NCT02692898 -
Biomarker Analysis of Central Nervous System Tumors
|
||
Completed |
NCT00328458 -
EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients
|
Phase 1 | |
Recruiting |
NCT04859543 -
Pediatric Prospective Personalized Immune and Target Identification Trial
|
N/A | |
Terminated |
NCT04096716 -
Mapping Draining Lymph Nodes in CNS Malignancies
|
Phase 1 | |
Completed |
NCT01931098 -
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
|
Phase 2 | |
Recruiting |
NCT05386108 -
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/HER2- Breast Cancer
|
Phase 1/Phase 2 |